China breaks new ground with reversal of first pharmaceutical deal
China’s antitrust regulator has broken new ground by unwinding a completed pharmaceutical acquisition, marking its first-ever full rollback of a consummated deal. In a historic move, the State Administration for Market Regulation...To view the full article, register now.
Already a subscriber? Click here to view full article